Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michalis Kostapanos

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
BMJ (Clinical Research Ed.)|January 24, 2024
StatinsSpoorthy Kulkarni, Michaela M Watts, Michalis Kostapanos
Antiviral Therapy|March 22, 2019
Effect of rifabutin on the pharmacokinetics of oral cabotegravir in healthy subjectsSusan L Ford, Yu Lou, Nicole Lewis, et al.
Rheumatology (Oxford, England)|January 27, 2021
Baricitinib set to join the Covid-19 therapeutic arsenal?Tania Gudu, Carmel Stober, Andrew P Cope, et al.
Plos Neglected Tropical Diseases|May 13, 2026
Safety and pharmacokinetics of GSK3494245, a highly selective Leishmaniasis kinetoplastid proteasome inhibitor for the treatment of visceral leishmaniasis: A Phase 1, randomized, single ascending dose escalation study in healthy participantsMischka Moodley, Michalis Kostapanos, Laura Iavarone, et al.
Trials|July 10, 2020
Repurposed immunomodulatory drugs for Covid-19 in pre-ICu patients - mulTi-Arm Therapeutic study in pre-ICu patients admitted with Covid-19 - Repurposed Drugs (TACTIC-R): A structured summary of a study protocol for a randomised controlled trialSpoorthy Kulkarni, Marie Fisk, Michalis Kostapanos, et al.
European Journal of Drug Metabolism and Pharmacokinetics|November 9, 2020
Comparison of the Pharmacokinetics of RIPK1 Inhibitor GSK2982772 in Healthy Western and Japanese SubjectsDebra J Tompson, Carwyn Davies, Nicola E Scott, et al.
Trials|August 2, 2020
muLTi-Arm Therapeutic study in pre-ICu patients admitted with Covid-19-Experimental drugs and mechanisms (TACTIC-E): A structured summary of a study protocol for a randomized controlled trialIng Ni Lu, Spoorthy Kulkarni, Marie Fisk, et al.
BMJ Open|September 19, 2018
Low-dose interleukin-2 in patients with stable ischaemic heart disease and acute coronary syndromes (LILACS): protocol and study rationale for a randomised, double-blind, placebo-controlled, phase I/II clinical trialTian Xiao Zhao, Michalis Kostapanos, Charmaine Griffiths, et al.
The Lancet. Respiratory Medicine|November 17, 2023
Efficacy and safety of baricitinib or ravulizumab in adult patients with severe COVID-19 (TACTIC-R): a randomised, parallel-arm, open-label, phase 4 trialFrances C Hall, Joseph Cheriyan, Andrew P Cope, et al.
Rheumatology (Oxford, England)|November 22, 2020
Advanced imaging for quantification of abnormalities in the salivary glands of patients with primary Sjögren's syndromePilar Jimenez-Royo, Michele Bombardieri, Coziana Ciurtin, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
BMJ (Clinical Research Ed.)|January 24, 2024
StatinsSpoorthy Kulkarni, Michaela M Watts, Michalis Kostapanos
Antiviral Therapy|March 22, 2019
Effect of rifabutin on the pharmacokinetics of oral cabotegravir in healthy subjectsSusan L Ford, Yu Lou, Nicole Lewis, et al.
Rheumatology (Oxford, England)|January 27, 2021
Baricitinib set to join the Covid-19 therapeutic arsenal?Tania Gudu, Carmel Stober, Andrew P Cope, et al.
Plos Neglected Tropical Diseases|May 13, 2026
Safety and pharmacokinetics of GSK3494245, a highly selective Leishmaniasis kinetoplastid proteasome inhibitor for the treatment of visceral leishmaniasis: A Phase 1, randomized, single ascending dose escalation study in healthy participantsMischka Moodley, Michalis Kostapanos, Laura Iavarone, et al.
Trials|July 10, 2020
Repurposed immunomodulatory drugs for Covid-19 in pre-ICu patients - mulTi-Arm Therapeutic study in pre-ICu patients admitted with Covid-19 - Repurposed Drugs (TACTIC-R): A structured summary of a study protocol for a randomised controlled trialSpoorthy Kulkarni, Marie Fisk, Michalis Kostapanos, et al.
European Journal of Drug Metabolism and Pharmacokinetics|November 9, 2020
Comparison of the Pharmacokinetics of RIPK1 Inhibitor GSK2982772 in Healthy Western and Japanese SubjectsDebra J Tompson, Carwyn Davies, Nicola E Scott, et al.
Trials|August 2, 2020
muLTi-Arm Therapeutic study in pre-ICu patients admitted with Covid-19-Experimental drugs and mechanisms (TACTIC-E): A structured summary of a study protocol for a randomized controlled trialIng Ni Lu, Spoorthy Kulkarni, Marie Fisk, et al.
BMJ Open|September 19, 2018
Low-dose interleukin-2 in patients with stable ischaemic heart disease and acute coronary syndromes (LILACS): protocol and study rationale for a randomised, double-blind, placebo-controlled, phase I/II clinical trialTian Xiao Zhao, Michalis Kostapanos, Charmaine Griffiths, et al.
The Lancet. Respiratory Medicine|November 17, 2023
Efficacy and safety of baricitinib or ravulizumab in adult patients with severe COVID-19 (TACTIC-R): a randomised, parallel-arm, open-label, phase 4 trialFrances C Hall, Joseph Cheriyan, Andrew P Cope, et al.
Rheumatology (Oxford, England)|November 22, 2020
Advanced imaging for quantification of abnormalities in the salivary glands of patients with primary Sjögren's syndromePilar Jimenez-Royo, Michele Bombardieri, Coziana Ciurtin, et al.
Pageof 2